EARLY DETECTION |
INSIGHTA

Led by World Class Science

Co-founded by world-renowned scientist, Prof. Dennis Lo, Insighta stands at the forefront of life sciences innovation. Leveraging Prof. Lo's groundbreaking work in non-invasive testing and backed by a team of world-class researchers, Insighta is set on a path to redefine early cancer detection. The goal – a simple blood draw to detect multiple types of cancers at their early stages, affordable enough for the World. This transformative approach is designed to drastically improve treatment success rates and ultimately save countless lives. Through this commitment to scientific excellence, Insighta aims to make early cancer detection an accessible reality for all, turning a new page in the global fight against cancer.

Saving Lives Through the Power of Early Cancer Detection

Our breakthrough technology detects cancers at the early stages, significantly improving the chances of treatment and ultimately saving lives.

Quantum Leap FRAGMA Liquid Biopsy Platform

Quantum Leap FRAGMA Liquid Biopsy Platform

Led by renowned scientist Prof. Dennis Lo, Insighta stands at the forefront of life sciences innovation. Leveraging Prof. Lo's groundbreaking work in non-invasive testing and backed by a team of world-class researchers, Insighta is set on a path to redefine early cancer detection. The goal – a simple blood draw to detect multiple types of cancers at their early stages, affordable enough for the World. This transformative approach is designed to drastically improve treatment success rates and ultimately save countless lives. Through this commitment to scientific excellence, Insighta aims to make early cancer detection an accessible reality for all, turning a new page in the global fight against cancer.

About FRAGMA Technology

FRAGMA provides an accurate and low cost method for studying the genomewide methylation profile of circulating DNA. As DNA methylation changes are hallmarks for a wide variety of cancers, this can be potentially applied to a multi-cancer early detection test.
Accurate and early detection of Liver Cancer (HCC - Hepatocellular carcinoma) with shallow-depth sequencing.
Versatile technology can be potentially applied for a MCED
Initial studies has also shown it is applicable for early detection for lung and colorectal cancer
Low cost, enabling accessibility of early detection cancer to a much wider population than current testing methods.
Urine DNA has shown to be valuable for the early detection of urogenital cancers

Cancer kills 10M people worldwide. Annually.

Early Detection can Potentially Benefit 1 billion+ People. Annually.

For Humanity, Saving Lives Through Early Detection